MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
43.30
-1.43
-3.20%
After Hours: 43.30 0 0.00% 17:01 12/05 EST
OPEN
45.05
PREV CLOSE
44.73
HIGH
46.01
LOW
43.02
VOLUME
745.46K
TURNOVER
--
52 WEEK HIGH
46.01
52 WEEK LOW
14.80
MARKET CAP
3.49B
P/E (TTM)
-21.3606
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Conmed (CNMD)
TipRanks · 1d ago
CG Oncology To Present Topline Data From BOND-003 Cohort P And First Results From CORE-008 Cohort A As Late-Breaking Abstracts At SUO 26th Annual Meeting
Benzinga · 1d ago
CG ONCOLOGY INC - CORE-008 COHORT A SHOWS PROMISING EFFICACY, TOLERABILITY AND SAFETY
Reuters · 1d ago
CG Oncology announces data from BOND-003 Cohort P, CORE-008 Cohort A
TipRanks · 1d ago
CG Oncology Reports Promising Results for Cretostimogene in High-Risk Bladder Cancer Trial
Reuters · 1d ago
Will CG Oncology’s (CGON) Board Refresh and Cretostimogene Data Shape Its Bladder Cancer Strategy?
Simply Wall St · 3d ago
Weekly Report: what happened at CGON last week (1124-1128)?
Weekly Report · 5d ago
A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements
Simply Wall St · 6d ago
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.